BioAge Labs (BIOA) vs Indaptus Therapeutics (INDP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BioAge Labs (BIOA) has outperformed Indaptus Therapeutics (INDP) over the past year, gaining 11.8% versus a loss of 38.8%. Indaptus Therapeutics is the larger company by market cap ($310.5 million vs $281.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIOA | INDP |
|---|---|---|
| Share price | $6.14 | $2.33 |
| Market cap | $281.81M | $310.45M |
| 1-day change | -1.92% | +3.10% |
| YTD return | -52.68% | -22.34% |
| 1-year return | +11.79% | -38.75% |
| 5-year return | — | -98.97% |
| EPS (TTM) | $-2.39 | $-6.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $25.96 | $5.96 |
| 52-week low | $5.04 | $0.92 |
| Distance from 52-week high | -76.34% | -60.91% |
| Analyst consensus | none | — |
| Avg. price target upside | +480.29% | — |
| Average volume | 913.77K | 829.14K |
| Shares outstanding | 45.90M | 133.24M |
| Employees | 60 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BIOA has outperformed INDP by 50.5 percentage points over the past year.
About BioAge Labs
BIOA stock →BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.
Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees
About Indaptus Therapeutics
INDP stock →Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
BIOA vs INDP FAQ
Which is bigger, BioAge Labs or Indaptus Therapeutics?
Indaptus Therapeutics (INDP) is larger, with a market capitalization of $310.45M compared with $281.81M for BioAge Labs (BIOA).
Which stock has performed better over the past year, BIOA or INDP?
BIOA returned +11.79% over the past 12 months, compared with -38.75% for INDP (price return, excluding dividends). Past performance does not predict future results.
Are BioAge Labs and Indaptus Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.